Suivre
Kylie Morphett
Kylie Morphett
Research Fellow, School of Public Health, University of Queensland
Adresse e-mail validée de uq.edu.au
Titre
Citée par
Citée par
Année
Why Don’t Smokers Want Help to Quit? A Qualitative Study of Smokers’ Attitudes towards Assisted vs. Unassisted Quitting
K Morphett, B Partridge, C Gartner, A Carter, W Hall
International Journal of Environmental Research and Public Health 12 (6 …, 2015
952015
Neurobehavioral differences between Alzheimer's disease and frontotemporal dementia: a meta-analysis
JL Mathias, K Morphett
Journal of clinical and experimental neuropsychology 32 (7), 682-698, 2010
572010
Closing the gaps in tobacco endgame evidence: a scoping review
C Puljević, K Morphett, M Hefler, R Edwards, N Walker, DP Thomas, ...
Tobacco control 31 (2), 365-375, 2022
492022
Framing and scientific uncertainty in nicotine vaping product regulation: An examination of competing narratives among health and medical organisations in the UK, Australia and …
DA Erku, S Kisely, K Morphett, KJ Steadman, CE Gartner
International Journal of Drug Policy 78, 102699, 2020
432020
Public attitudes in A ustralia towards the claim that addiction is a (brain) disease
C Meurk, B Partridge, A Carter, W Hall, K Morphett, J Lucke
Drug and alcohol review 33 (3), 272-279, 2014
372014
Beliefs and self-reported practices of health care professionals regarding electronic nicotine delivery systems: a mixed-methods systematic review and synthesis
DA Erku, CE Gartner, K Morphett, KJ Steadman
Nicotine and Tobacco Research 22 (5), 619-629, 2020
352020
Scepticism and hope in a complex predicament: People with addictions deliberate about neuroscience
C Meurk, K Morphett, A Carter, M Weier, J Lucke, W Hall
International Journal of Drug Policy 32, 34-43, 2016
322016
Does the content and source credibility of health and risk messages related to nicotine vaping products have an impact on harm perception and behavioural intentions? A …
DA Erku, L Bauld, L Dawkins, CE Gartner, KJ Steadman, SM Noar, ...
Addiction 116 (12), 3290-3303, 2021
292021
Policy debates regarding nicotine vaping products in Australia: a qualitative analysis of submissions to a government inquiry from health and medical organisations
DA Erku, K Morphett, KJ Steadman, CE Gartner
International Journal of Environmental Research and Public Health 16 (22), 4555, 2019
252019
What does ‘acceptance’mean? Public reflections on the idea that addiction is a brain disease
C Meurk, W Hall, K Morphett, A Carter, J Lucke
BioSocieties 8, 491-506, 2013
252013
Barriers and facilitators to switching from smoking to vaping: Advice from vapers
K Morphett, M Weier, R Borland, HH Yong, C Gartner
Drug and alcohol review 38 (3), 234-243, 2019
242019
Smokers’ understandings of addiction to nicotine and tobacco: a systematic review and interpretive synthesis of quantitative and qualitative research
D Pfeffer, B Wigginton, C Gartner, K Morphett
Nicotine and tobacco research 20 (9), 1038-1046, 2018
242018
Framing tobacco dependence as a “brain disease”: Implications for policy and practice
K Morphett, A Carter, W Hall, C Gartner
Nicotine & Tobacco Research 19 (7), 774-780, 2017
242017
Electronic nicotine delivery systems (e-cigarettes) as a smoking cessation aid: a survey among pharmacy staff in Queensland, Australia
DA Erku, CE Gartner, JT Do, K Morphett, KJ Steadman
Addictive behaviors 91, 227-233, 2019
222019
Medicalisation, smoking and e-cigarettes: evidence and implications
K Morphett, A Carter, W Hall, C Gartner
Tobacco control 26 (e2), e134-e139, 2017
212017
Predicting vaping uptake, vaping frequency and ongoing vaping among daily smokers using longitudinal data from the International Tobacco Control (ITC) Four Country Surveys
G Chan, K Morphett, C Gartner, J Leung, HH Yong, W Hall, R Borland
Addiction 114, 61-70, 2019
202019
A first pass, using pre‐history and contemporary history, at understanding why Australia and England have such different policies towards electronic nicotine delivery systems …
V Berridge, W Hall, S Taylor, C Gartner, K Morphett
Addiction 116 (9), 2577-2585, 2021
162021
Nicotine vaping product use, harm perception and policy support among pharmacy customers in Brisbane, Australia
DA Erku, CE Gartner, U Tengphakwaen, K Morphett, KJ Steadman
Drug and Alcohol Review 38 (6), 703-711, 2019
152019
Nicotine vaping products as a harm reduction tool among smokers: Review of evidence and implications for pharmacy practice
D Erku, CE Gartner, K Morphett, CL Snoswell, KJ Steadman
Research in Social and Administrative Pharmacy 16 (9), 1272-1278, 2020
142020
A qualitative study of smokers’ views on brain-based explanations of tobacco dependence
K Morphett, A Carter, W Hall, C Gartner
International Journal of Drug Policy 29, 41-48, 2016
142016
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20